PMID- 24687539
OWN - NLM
STAT- MEDLINE
DCOM- 20150512
LR  - 20211021
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Linking)
VI  - 22
IP  - 9
DP  - 2014 Sep
TI  - Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative 
      cohort study to explore the influence of patient-reported outcomes on therapy 
      decisions.
PG  - 2371-80
LID - 10.1007/s00520-014-2223-2 [doi]
AB  - PURPOSE: Optimal long-lasting treatment with sunitinib and sorafenib is limited 
      by dose modifications (DMs) due to adverse events (AEs). These AEs may be 
      underrecognized and their influence on health-related quality of life (HRQL) 
      underestimated. Improved insight into the relationship between AEs and therapy 
      decisions is needed. To improve decision making around managing symptoms and 
      reduce DMs, this study was set up to explore the influence of patient-reported 
      symptoms on therapy decisions. METHODS: In this multicenter cohort study, patient 
      characteristics, reasons for and different forms of used dose modifications, and 
      AEs were prospectively obtained from cancer patients on sunitinib/sorafenib 
      treatment. Used instruments to get insight into AEs were the patient-scored 
      Utrecht Symptom Diary (USD) and the professional-scored Common Terminology 
      Criteria for AEs version 3.0. RESULTS: Median total treatment duration in 42 
      patients was 16 weeks. Median time till dose modification was 10 weeks. DMs 
      occurred mostly due to multiple mild AEs. By using the USD, a higher prevalence 
      of most AEs was found compared to the literature. Sixty percent of the patients 
      experienced a decreased HRQL due to multiple AEs. CONCLUSIONS: Because severe AEs 
      due to sunitinib/sorafenib treatment seldom occur, it is more important to focus 
      on treating and preventing multiple mild AEs with higher impact on HRQL, when 
      trying to avoid dose modifications. Using patient self-reported measurement 
      methods helps to early recognize symptoms and to differentiate among symptom 
      intensities. This systematic approach might help to achieve the optimal dosing, 
      which might improve PFS and OS.
FAU - Koldenhof, J J
AU  - Koldenhof JJ
AD  - Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 
      100, 3584 CX, Utrecht, The Netherlands, j.koldenhof@umcutrecht.nl.
FAU - Witteveen, P O
AU  - Witteveen PO
FAU - de Vos, R
AU  - de Vos R
FAU - Walraven, M
AU  - Walraven M
FAU - Tillier, C N
AU  - Tillier CN
FAU - Verheul, H M W
AU  - Verheul HM
FAU - Teunissen, S C C M
AU  - Teunissen SC
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20140402
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Indoles)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyrroles)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/administration & dosage/*adverse effects
MH  - Cohort Studies
MH  - Decision Making
MH  - Female
MH  - Humans
MH  - Indoles/administration & dosage/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*drug therapy
MH  - Netherlands
MH  - Niacinamide/administration & dosage/adverse effects/*analogs & derivatives
MH  - Phenylurea Compounds/administration & dosage/*adverse effects
MH  - Pyrroles/administration & dosage/*adverse effects
MH  - Quality of Life
MH  - *Self Report
MH  - Sorafenib
MH  - Sunitinib
MH  - Treatment Outcome
EDAT- 2014/04/02 06:00
MHDA- 2015/05/13 06:00
CRDT- 2014/04/02 06:00
PHST- 2013/05/15 00:00 [received]
PHST- 2014/03/20 00:00 [accepted]
PHST- 2014/04/02 06:00 [entrez]
PHST- 2014/04/02 06:00 [pubmed]
PHST- 2015/05/13 06:00 [medline]
AID - 10.1007/s00520-014-2223-2 [doi]
PST - ppublish
SO  - Support Care Cancer. 2014 Sep;22(9):2371-80. doi: 10.1007/s00520-014-2223-2. Epub 
      2014 Apr 2.